Answers are grounded in this paper and cite their sources.
The emergence of multidrug-resistant microbes is a never-ending threat and remains a major challenge in modern infectious diseases treatment and control. While most attention and public health efforts have been focused on multidrug-resistant bacteria, an alert has recently been issued about the potential of multiple outbreaks of the uncommon multidrug-resistant Candida auris. The recent global spread of this previously unknown yeast that can be transmitted nosocomially is intriguing and poses interesting questions regarding its epidemiology, pathogenesis, management, and infection control. The first descriptions of Candida auris came from publications from Japan and South Korea in 2009 [1, 2] and involved isolates initially misidentified by conventional biochemical tests. Since that time, invasive infections due to C. auris have been reported from all continents and with increasing frequency (Figure 1) [3], although prevalence in many parts of the world is difficult to estimate. In India, C. auris ranked as the fifth cause of candidemia in intensive care units, accounting for 5.3% of cases [4]. Several outbreaks have been reported, with the largest (>50 cases each) occurring in the United Kingdom (during 2015–2016) and Spain (during 2016–2017) [5, 6]. Genotypic analyses identified distinct clades for each geographical region and the same clonal origin within each clade [3, 7–10], suggesting that C. auris was introduced at different sites and disseminated locally. In the United States, as of 30 September 2017, 166 clinical cases of C. auris have been reported (mostly in New York and New Jersey), and 184 additional cases were identified by screening close contacts of patients [11]. The in vitro susceptibility of C. auris isolates to antifungal drugs is variable. In the absence of clinical breakpoints, different thresholds of susceptibility extrapolated from closely related Candida species have been proposed [3, 4, 7]. Most C. auris isolates are resistant to fluconazole (minimum inhibitory concentration [MIC] required to inhibit growth of 90% of organisms, ≥64 µg/mL) [3, 4, 7, 12]. In vitro resistance to voriconazole is variable (range, 3%–73% of isolates), while other triazoles (posaconazole, itraconazole, and isavuconazole) display better activity [3, 4, 7, 12]. Resistance to amphotericin B was reported in 13%–35% of isolates [3, 4, 7]. While most isolates are susceptible to echinocandins, MICs are higher than those for Candida albicans [3, 4, 7, 12]. Echinocandins are the most effective drugs in animal models [13]. Of concern, about 40% of C. auris isolates are resistant to ≥2 antifungal drug classes, and 4%–10% are resistant to most antifungal agents [3, 12]. Deciphering the mechanisms of resistance in C. auris is work in progress. Several erg11 mutations known to be associated with azole resistance have been identified and were related to distinct geographical clades [3]. Functional genome annotation showed that the C. auris genome encodes multiple transporters of the ABC family and the major facilitator superfamily and is phylogenetically close to that of Candida lusitaniae, another fungus capable of rapid induction of resistance [14]. Sequencing of hotspots in the fks genes of C. auris isolates with elevated echinocandin MICs did not detect any mutation [10, 12]. Because C. auris was unknown before 2009, the question arises whether this species is a newcomer in the world of pathogenic fungi or simply has been not previously recognized. Isolates of C. auris have been commonly misidentified as Candida haemulonii, Candida famata, Rhodotorula glutinis, Saccharomyces cerevisiae, or unspecified Candida species. using conventional biochemical diagnostic procedures. The advent of molecular techniques and recent improvements in mass spectrometry (ie, matrix-assisted laser desorption ionization–time of flight [MALDI-TOF] mass spectrometry) databases allow better recognition of this pathogen. Although C. auris was identified in a few clinical samples 20 years ago [2, 15], several lines of evidence indicate that C. auris has emerged as a novel pathogenic Candida species only during the last decade. Analysis of the international SENTRY collection (15271 Candida isolates, collected between 2004 and 2015) identified only 4 C. auris isolates, all collected since 2009 [3]. None of the US cases were identified prior to 2013 [16]. The fact that C. auris infections are mainly observed among patients with previous antifungal exposure suggests that selective pressure could have played a role in the emergence of this novel pathogen [3, 4]. However, the shift in Candida epidemiology, with an increasing proportion of non-albicans and azole-resistant Candida species, has long preceded the emergence of C. auris [17]. The emergence of C. auris as a human pathogen could have been linked to the acquisition of new virulence traits. However, the identification of distinct geographical clades indicates that this genetic event should have occurred simultaneously and independently in different parts of the world (Figure 1) [3, 9]. Our understanding of pathogenesis of C. auris infection is in early stages, although promising genome modification systems are being developed [18]. C. auris possesses the armamentarium required to infect humans and shares virulence traits encountered in other pathogenic Candida species, including host cell adherence, biofilm formation, and invasive properties [13, 19]. The virulence of C. auris appears to be comparable to that of C. albicans in experimental mouse and Galleria models of infection [19, 20] and higher than that of C. albicans in Toll-deficient flies (D. P. Kontoyiannis, unpublished data). Other intriguing questions regarding the pathogenesis of C. auris remain open: What can we learn by comparative genomic analysis of C. auris versus C. albicans? Is there strain-strain variability to virulence, host responses, and propensity of invasive disease/dissemination? Is C. auris a permissive or conditional part of human mycobiome? Is there a natural reservoir and an event that triggered a change of its ecological niche to affect humans? Geographical distribution of Candida auris cases and outbreaks reported in the world. Only cases reported in the medical literature are shown. The size of the circles is representative of the number of cases. The colors represent the different clades that have been described. Cases from the United States and Great Britain are distributed in different clades. C. auris exhibits all the characteristics of a pathogen of public health concern, comparable to multidrug-resistant bacteria such as methicillin-resistant Staphylococcus aureus, or carbapenemase-producing Enterobacteriaceae. These include (1) the potential to spread by horizontal transmission and cause outbreaks; (2) the ability to cause severe, even fatal disease; and (3) the multidrug-resistant profile and paucity of antimicrobial armamentarium. Contrary to most Candida infections, which arise from the commensal flora, C. auris has high potential for interhuman transmission. Isolates recovered from the same healthcare unit shared the same clonal origin [3, 5, 7, 8]. Moreover, isolates from the same cluster were recovered in distant hospitals within a same region, supporting modes of transmission within the community. The introduction of C. auris in the United Kingdom and the United States is believed to have resulted from travelers having received healthcare in countries where the fungus is endemic [5, 16]. However, other unknown modes of propagation are possible. C. auris has the ability to form biofilms on polymeric surfaces and has been recovered in environmental samples from hospital rooms during outbreaks [5, 6, 21]. In vitro studies showed that, despite forming less biofilm than C. albicans, C. auris has a greater capacity to persist and survive on dry or moist surfaces [22–24]. Similar persistence properties were described for Candida parapsilosis [24], but evidence of nosocomial transmission of C. parapsilosis or other Candida species has been only anecdotally reported [25, 26]. Actually, C. auris may exhibit 2 phenotypes: an aggregative form with enhanced resistance to physical or chemical disruption, favoring persistence in the environment or in the host, and a nonaggregative form with higher capacity to form biofilm [19, 21]. The association between C. auris infections and invasive procedures further supports the risk of nosocomial transmission via contaminated medical devices [4]. Overall mortality of C. auris infections is high (40%–60%), which is due in part to the severe underlying conditions of the patients and the multidrug-resistant nature of this pathogen [3–5], as persistent candidemia is common [7, 8]. The limited therapeutic choices in conjunction with the nosocomial persistence of the fungus raise the nightmarish scenario of large-scale nosocomial outbreaks. It is difficult to predict the impact of C. auris epidemics or even pandemics in the future, but this certainly depends on the actions that will be undertaken at this stage to manage this urgent situation. Strategies of prevention and infection control should be of paramount importance for C. auris, as it should be for all multidrug-resistant nosocomial microbes (Table 1). Sporicidal surface disinfectants, such as peroxide hydrogen vapor and sodium hypochlorite–based agents used against Clostridium difficile, are active, while quaternary ammonium disinfectants are not [5, 27]. Chlorhexidine is active against C. auris and has been used for skin decolonization of cases detected by contact screening, but persistent colonization is common [5, 21]. Identification of potential reservoirs and early recognition of cases, including systematic screening of patients coming from a region with high prevalence of C. auris infection, are important to prevent outbreaks. Screening of multiple sites is recommended, including groin, axilla, and nares [28]. Such screening might be also important for the safety of organ transplantation, as donor-derived transmission of C. auris has been already described [29]. Hallmarks Making Candida auris a Major Public Health Issue and Proposed Interventions Abbreviation: MALDI-TOF, matrix-assisted laser desorption ionization–time of flight. Hallmarks Making Candida auris a Major Public Health Issue and Proposed Interventions Abbreviation: MALDI-TOF, matrix-assisted laser desorption ionization–time of flight. The optimal treatment of C. auris infection remains to be defined. Echinocandins are currently recommended as first-line treatment because most isolates are susceptible. Addition of amphotericin B is recommended by experts in case of persistent fungemia or lack of clinical response [28]. The role of isavuconazole, the most active triazole in vitro, should be further defined. Drug combinations should also be investigated, because synergistic interactions between voriconazole and micafungin were observed [30]. Antifungal treatment is not recommended for patients who are only colonized. In view of the frequent resistance of C. auris to modern antifungals, there is a need to expand our preclinical and ultimately clinical testing to investigational antifungals [31]. For example, a potent inhibitory effect and antibiofilm activity has been shown with the novel 1,3-β-d-glucan synthase inhibitor SCY-078 [22]. The mycology community needs also to invest more in studying the epidemiology and diagnosis of C. auris infections. Large epidemiological surveys and international networks, such as the SENTRY antifungal surveillance program, have been developed, but data are lacking for many parts of the world. Improving access to molecular tools and MALDI-TOF mass spectrometry in developing countries is important. Finally, education of the public and of healthcare providers should be complementary to infection control, antifungal stewardship, and containment efforts. The unprecedented emergence of C. auris is a timely reminder that, as with many bacteria, fungal pathogens deserve equal attention from policy makers, scientists, drug developers, and treating physicians. Potential conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Lamoth et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: